Clinical Trial Update: BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia [Phase 2]

View source ↗

Summary

Phase 2 trial of BYM338 in patients with chronic obstructive pulmonary disease and cachexia completed; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cachexia
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BYM338

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease (COPD) With Cachexia | Phase 2 | Status: COMPLETED | Results posted: 2016-05-03